Glaxo to reap $890M as it halves stake in South Africa’s Aspen

Carly Helfand

Less than a year and a half ago, GlaxoSmithKline decided to sell off a chunk of its in fast-growing Pharmacare and the rewards from its investment. And now, it's doing the same thing again–this time with a larger piece.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS